The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALPINE IMMUNE SCIENCES INC | COM | 02083G100 | 24,211,256 | 3,136,173 | SH | OTR | 1 | 0 | 3,136,173 | 0 | ||
| BELLUS HEALTH INC NEW | COM NEW | 07987C204 | 6,239,851 | 866,646 | SH | OTR | 1 | 0 | 866,646 | 0 | ||
| CABALETTA BIO INC | COM | 12674W109 | 20,299,765 | 2,454,627 | SH | OTR | 1 | 0 | 2,454,627 | 0 | ||
| CYMABAY THERAPEUTICS INC | COM | 23257D103 | 11,945,763 | 1,369,927 | SH | OTR | 1 | 0 | 1,369,927 | 0 | ||
| KINNATE BIOPHARMA INC | COM | 49705R105 | 13,839,063 | 2,214,250 | SH | OTR | 1 | 0 | 2,214,250 | 0 | ||
| MERUS N V | COM | N5749R100 | 19,646,103 | 1,067,723 | SH | OTR | 1 | 0 | 1,067,723 | 0 | ||
| NEOLEUKIN THERAPEUTICS INC | COM | 64049K104 | 1,699,826 | 2,428,323 | SH | OTR | 1 | 0 | 2,428,323 | 0 | ||
| PARDES BIOSCIENCES INC | COM | 69945Q105 | 4,387,761 | 3,324,061 | SH | OTR | 1 | 0 | 3,324,061 | 0 | ||
| PASSAGE BIO INC | COM | 702712100 | 3,263,457 | 3,407,598 | SH | OTR | 1 | 0 | 3,407,598 | 0 | ||
| PHARVARIS N V | COM | N69605108 | 211,242 | 26,225 | SH | OTR | 1 | 0 | 26,225 | 0 | ||
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 6,898,093 | 7,067,718 | SH | OTR | 1 | 0 | 7,067,718 | 0 | ||
| STRUCTURE THERAPEUTICS INC | SPONSORED ADS | 86366E106 | 547,170 | 23,000 | SH | OTR | 1 | 0 | 23,000 | 0 | ||
| THESEUS PHARMACEUTICALS INC | COM | 88369M101 | 6,759,971 | 761,258 | SH | OTR | 1 | 0 | 761,258 | 0 | ||